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Introduction
Genomics represents a new tool in drug
discovery.  Microbial genomics have been
at the forefront of a new era of whole cell
molecular biology because genomic data
provides a quantum leap in available
genetic data.  But while the tool is
valuable and important, it is not the
complete answer.  
While releasing vast amounts of genetic
code, the microbial genomes pose new
questions, especially in terms of the large
amounts of genetic information that
cannot be categorised by function.  Today
we are beginning to undertake systematic
studies of the network of interactions of
genes and gene products that must be
met if we are to increase our awareness of
microbial physiology and pathogenesis
and, ultimately, the management of
disease.
How does genomics aid in drug
discovery?  This question can be
answered in part by reference to
technologies as diverse as bioinformatics,
microarray technology, functional
genomics, proteomics and high
throughput screening.  Specifically, we
can look at the identification of novel
therapeutic targets through a more
complete understanding of the
biochemistry and physiology of an
organism.  In addition we can seek to
enhance our understanding of disease
processes at the molecular level to reveal
key determinants of virulence that may
represent potential drug targets.  
A major leap forward will be our capacity to
undertake genome sequence comparisons
(microbe-human or microbe-microbe)
allowing identification of targets having the
highest potential to minimise toxic side
effects in the host or undesirable
interactions (e.g. perturbation of the
normal microbiota). 
To achieve some of the above requires
new approaches.  A clear example is high
throughput screening.  Using technology
such as microarrays and proteomics,
whole genome expression profiles can be
used to identify putative targets and so
enhance the drug discovery process.  This
includes the potential to examine the
interactions between genes and/or
expressed proteins such as in signal
transduction.  Once a target has been
identified it is hoped that new chemical
entities can be developed that may avoid
the resistance problems associated with
‘natural’ antibiotics.  The design of novel
chemical entities is being enhanced by
the growing capacity to predict protein
structures from genomic data (‘structural
genomics’) and thereby accelerate drug
design. 
Yet genome comparisons represent only
the first steps in the exploitation of
genomic data for drug discovery 1.  Genes
identified as being ‘unique’ and thus of
interest need to be further interrogated
looking for clues to function.  Having
identified a function for a potential drug
target it is then necessary to establish that
the target is essential prior to undertaking
inhibitor synthesis.  This in itself can be
problematic as we are beginning to fully
appreciate that a gene product that is not
essential in vitro may be essential in vivo.
Microarrays
DNA microarray technology is one
approach to gene function discovery.
This is based on the simultaneous
interrogation of a complete set of genes
within a given organism.  The genes of
interest are arrayed on a suitable support
and thus can be used as probes that may,
for example, be used to explore gene
expression within a prescribed set of
circumstances 2.  One example of this
approach has been the demonstration in
Mycobacterium tuberculosis 3 that the
antibiotic isoniazid induced genes
encoding for proteins physiologically
related to the mode of action of the drug.  
To test their observations further, the
authors tested the effect of ethionamide
(which inhibits the same metabolic
pathway) and noted that this drug
induced the same genes as isoniazid.
This research team also noted selected
genes were not induced in isoniazid
resistant isolates.  Importantly, by using a
microarray the authors discovered a
number of genes induced by isoniazid
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Representation of the generation, probing and analysis of a microarray.
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that encoded proteins not known to be
related to the mode of action of the drug.
Thus potential new drug targets in
isoniazid sensitive and resistant strains
could be identified.  Therefore one
objective may be considered the removal
of ‘bottle necks’ in the process of target
identification 4, 5.
Structural genomics
As noted in a recent review in Science 6,
structural biology has turned the corner.
We are seeing today that modelling and
high speed computing is allowing greater
accuracy in the processes of predicting
protein structure.  
U N D E R  T H E  M I C R O S C O P E
This approach has limitations, a classic
example being the impact of molecular
chaperones on the final conformation of a
protein.  However, it is not unreasonable
to expect that advances in this field will
facilitate the development of better
computational systems.  
We are approaching a time when
biomedical science will have the tools that
will allow both the identification of novel
therapeutic targets and allow us to model
drug-target interactions.  That is, identify
targets and design novel lead compounds
in silico. Indeed, we may even be able to
test for potential adverse effects and/or
selective toxicity using the same
technology.
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Old therapies, new science
With the emergence of antibiotic
resistance as a major public health
problem and the apparent decline in
pharmaceutical company drive to
produce new antimicrobials, there has
been an increase in interest in revisiting
remedies and agents once popular before
the advent of the antibiotic era 1.  
This makes sense – it is obvious that many
of these therapies worked hundreds if not
thousands of years ago, although the
scientific basis of some is rather obscure.
With others, however, good data exist on
both in vitro and in vivo efficacy.
Randomised clinical trials have been
completed with good outcomes.  Three
compounds or groups of compounds
used in traditional medicine – in which
there has been a major resurgence of
interest in the last 30 years to the extent
that one has become an accepted therapy
– are garlic, artesunate and essential oils.
Garlic
Garlic (Allium sativum) was once used by
millions to ward off vampires and was first
prescribed in 3000 BC by the Sumerians, a
group who lived and still live in present
day Iraq.  Garlic has a wide spectrum of
action and is considered to be
antibacterial, antiviral, antifungal and
antiprotozoal 2.  
However, although garlic has been used
for its medicinal properties for thousands
of years, investigations into its mode of
action have only occurred relatively
recently.  Early steps in identifying the
active constituents of garlic were the
discovery that the compound allicin (allyl
2-propene thiosulphinate) is formed
when garlic is crushed and that its
formation depends on the action of the
enzyme allinase.  
Methyl and allyl sulphide derivatives of
allicin are formed by the steam distillation
of crushed garlic 3.  The diallyl sulphide
components of garlic oil are the most
active and this activity is inversely
proportional to the number of disulphide
bonds, diallyl monosulphide having
greatest activity.  These diallyl sulphides
inhibit various bacteria and fungi at
concentrations similar to conventional
antimicrobials 4.  
Several recent studies have shown good
activity of garlic materials against
Helicobacter pylori 5 and clearly garlic has
a long history of safe use.  Epidemiological
studies show a reciprocal relationship
between gastric cancer, which is strongly
correlated with H. pylori infection, and
the consumption of Allium vegetables 6,
suggesting the further investigation of
garlic as an antimicrobial is warranted.
Artesunate
Traditional Chinese medicine has
provided us with qinghaosu for the
treatment of malaria.  The isolation of
artemisinin in 1972 by a Chinese scientist
lead to the development of a number of
derivatives and an impressive body of
work relating to the understanding of the
chemistry, pharmacological profiles,
toxicology, metabolism and effects on the
malaria parasite 7.
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